Management of Rheumatoid Arthritis with Pulmonary Involvement

Introduction to Treatment Guidelines

The American College of Rheumatology recommends avoiding methotrexate and leflunomide in patients with rheumatoid arthritis and active interstitial lung disease, instead prioritizing tocilizumab or rituximab as first-line biologic therapies, with close monitoring using high-resolution chest CT every 3-6 months 1

The American College of Rheumatology suggests that abatacept can be considered as a third option in refractory cases 2

The European League Against Rheumatism recommends initiating tocilizumab 8 mg/kg IV every 4 weeks or 162 mg SC weekly, adding prednisone ≤7.5 mg/day for a maximum of 6 months, then rapidly reducing, and avoiding high doses of glucocorticoids (>10 mg/day) due to the risk of infections and osteoporosis 1, 2
The American College of Rheumatology suggests evaluating disease activity every 1-3 months using CDAI or SDAI until remission or low activity is achieved, with regular chest CT and pulmonary function tests every 6 months 3, 4

The American College of Rheumatology recommends supervised aerobic exercise and muscle strengthening to maintain functional capacity, as well as occupational therapy for joint protection techniques and assistive devices 5, 6
The American College of Rheumatology suggests that smoking cessation is obligatory, as smoking is a modifiable risk factor for rheumatoid arthritis and interstitial lung disease progression 7

The American College of Rheumatology advises against using methotrexate in patients with interstitial lung disease, as it is a relative contraindication 1
The European League Against Rheumatism recommends not delaying the initiation of biologics, as time is critical to prevent irreversible fibrosis in active interstitial lung disease 8